Comparison · Updated
Sermorelin VS Tesamorelin
Short answer
Sermorelin and Tesamorelin have the same evidence tier: both are tier S (Approved).
Sermorelin was FDA-approved (Geref, 1997) and later discontinued; Tesamorelin is FDA-approved (Egrifta, 2010).
Both are prohibited in sport by WADA under section S2.
01
Side by side
| Field | Sermorelin | Tesamorelin |
|---|---|---|
| Evidence tier | S Tier S · Approved | S Tier S · Approved |
| Tier rationale | Previously FDA-approved (Geref) for diagnosis and treatment of GH deficiency in children; withdrawn from the market in 2008 for commercial reasons. | FDA-approved (Egrifta) to reduce excess abdominal fat in HIV-associated lipodystrophy, based on phase 3 RCTs. |
| FDA status | Approved 1997, later discontinued GerefApproved for pediatric GH deficiency; discontinued 2008, not for safety reasons. | Approved (2010) EgriftaReduction of excess abdominal fat in adults with HIV and lipodystrophy. |
| Other approvals | None listed | None listed |
| WADA | Prohibited · S2Peptide hormones, growth factors, related substances and mimetics | Prohibited · S2Peptide hormones, growth factors, related substances and mimetics |
| Family | GH & Growth | GH & Growth |
| Residues | Not on file | Not on file |
| Molecular weight | Not on file | Not on file |
| Formula | Not on file | Not on file |
| Discovered | Not on file | Not on file |
| Routes studied | Subcutaneous, Intramuscular | Subcutaneous, Intramuscular |
| Mechanism | Sermorelin (GHRH 1-29) is the biologically active N-terminal fragment of endogenous GHRH. It binds the GHRH receptor on anterior pituitary somatotrophs and activates cAMP/PKA signaling to promote GH gene transcription and pulsatile GH release. | Tesamorelin is a synthetic GHRH analog with a trans-3-hexenoic acid modification that increases enzymatic stability. It binds the GHRH receptor on pituitary somatotrophs, stimulating physiological GH release. |
| Safety notes | Previously FDA-approved (Geref) with a well-established safety record. | FDA-approved (Egrifta) with Phase III safety data. |
| Cited studies | 0 studies | 0 studies |
02
Questions
- Which has stronger evidence, Sermorelin or Tesamorelin?
- Sermorelin and Tesamorelin have the same evidence tier: both are tier S (Approved). Sermorelin: Previously FDA-approved (Geref) for diagnosis and treatment of GH deficiency in children; withdrawn from the market in 2008 for commercial reasons. Tesamorelin: FDA-approved (Egrifta) to reduce excess abdominal fat in HIV-associated lipodystrophy, based on phase 3 RCTs. Tiers rate the strength of published evidence, not effectiveness.
- Is Sermorelin FDA-approved?
- Sermorelin was FDA-approved (Geref, 1997) and later discontinued. Approved for pediatric GH deficiency; discontinued 2008, not for safety reasons.
- Is Tesamorelin FDA-approved?
- Tesamorelin is FDA-approved (Egrifta, 2010). Reduction of excess abdominal fat in adults with HIV and lipodystrophy.
- Are Sermorelin and Tesamorelin banned in sport?
- Both are prohibited in sport by WADA under section S2.
- How do Sermorelin and Tesamorelin work?
- Sermorelin (GHRH 1-29) is the biologically active N-terminal fragment of endogenous GHRH. Tesamorelin is a synthetic GHRH analog with a trans-3-hexenoic acid modification that increases enzymatic stability.